Here the authors show that intermittent, but not continuous, treatment with an anti-PI3Kα/β/δ-inhibitor promotes anti-tumor immunity and response to PD-1 blockade in a preclinical Pten-null model of prostate cancer. This evidence concerns the gene PTEN and Familial prostate cancer.